このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Vertex Pharmaceuticals マネジメント

マネジメント基準チェック /24

Vertex Pharmaceuticals'の CEO はReshma Kewalramaniで、 Apr2020年に任命され、の在任期間は 4.17年です。の年間総報酬は$ 20.59Mで、 7.3%給与と92.7%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.018%を直接所有しており、その価値はR$ 117.42M 。経営陣と取締役会の平均在任期間はそれぞれ4.7年と4.3年です。

主要情報

Reshma Kewalramani

最高経営責任者

US$20.6m

報酬総額

CEO給与比率	7.3%
CEO在任期間	4.2yrs
CEOの所有権	0.02%
経営陣の平均在職期間	4.7yrs
取締役会の平均在任期間	4.3yrs

経営陣の近況

Recent updates

CEO報酬分析

Vertex Pharmaceuticals の収益と比較して、Reshma Kewalramani の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	US$4b
Dec 31 2023	US$21m	US$2m	US$4b
Sep 30 2023	n/a	n/a	US$3b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$3b
Dec 31 2022	US$16m	US$1m	US$3b
Sep 30 2022	n/a	n/a	US$3b
Jun 30 2022	n/a	n/a	US$3b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	US$15m	US$1m	US$2b
Sep 30 2021	n/a	n/a	US$2b
Jun 30 2021	n/a	n/a	US$2b
Mar 31 2021	n/a	n/a	US$3b
Dec 31 2020	US$9m	US$1m	US$3b
Sep 30 2020	n/a	n/a	US$3b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$7m	US$702k	US$1b

報酬と市場: Reshmaの総報酬 ($USD 20.59M ) は、 BR市場 ($USD 5.83M ) の同規模の企業の平均を上回っています。

報酬と収益: Reshmaの報酬は過去 1 年間で 20% 以上増加しました。

CEO（最高経営責任者

Reshma Kewalramani (51 yo)

4.2yrs

在職期間

US$20,594,441

報酬

Dr. Reshma Kewalramani, M.D., FASN, is Director at Year Up Inc. since September 2023. She has been an Independent Director of Ginkgo Bioworks Holdings, Inc. (formerly known as Ginkgo Bioworks, Inc.) since...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jeffrey Leiden	Executive Chairman	14.9yrs	US$6.60m	0.0055% $ 36.5m
Reshma Kewalramani	CEO, President & Director	4.2yrs	US$20.59m	0.018% $ 117.3m
Charles Wagner	Executive VP & CFO	5.2yrs	US$7.37m	0.018% $ 121.1m
Stuart Arbuckle	Executive VP & COO	2.9yrs	US$9.00m	0.019% $ 128.0m
David Altshuler	Executive VP & Chief Scientific Officer	9.4yrs	US$6.54m	0.010% $ 66.3m
Kristen Ambrose	Senior VP & Chief Accounting Officer	3.1yrs	データなし	0.0029% $ 19.3m
Mike Tirozzi	SVP and Chief Information & Data Officer	5.4yrs	データなし	データなし
Susie Lisa	Senior Vice President of Investor Relations	1.8yrs	データなし	データなし
Jonathan Biller	Executive VP & Chief Legal Officer	1.8yrs	データなし	0.0071% $ 46.9m
Nina Devlin	Senior VP & Chief Communications Officer	5.4yrs	データなし	データなし
Stephanie Franklin	Senior VP & Chief Human Resources Officer	6.8yrs	データなし	データなし
Amit Sachdev	Executive VP & Chief Patient and External Affairs Officer	16.9yrs	US$6.20m	0.023% $ 149.4m

4.7yrs

平均在職期間

57yo

平均年齢

経験豊富な経営陣: VRTX34の経営陣は経験豊富であると考えられます ( 4.7年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Jeffrey Leiden	Executive Chairman	14.9yrs	US$6.60m	0.0055% $ 36.5m
Reshma Kewalramani	CEO, President & Director	4.3yrs	US$20.59m	0.018% $ 117.3m
Bruce Sachs	Lead Independent Director	26.4yrs	US$600.04k	0.015% $ 102.7m
Alan Garber	Independent Director	7yrs	US$537.63k	0.0023% $ 15.1m
Lloyd Carney	Independent Director	5.3yrs	US$559.79k	0.0021% $ 13.7m
Sangeeta Bhatia	Independent Director	9yrs	US$550.31k	0.0013% $ 8.8m
Michel Lagarde	Independent Director	less than a year	US$449.08k	データなし
Diana McKenzie	Independent Director	4yrs	US$553.11k	0.00064% $ 4.2m
Suketu Upadhyay	Independent Director	2.1yrs	US$544.66k	0.00060% $ 4.0m
Nancy Thornberry	Independent Director	less than a year	US$407.65k	データなし
Jennifer Schneider	Independent Director	less than a year	データなし	データなし

4.3yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: VRTX34の取締役会は経験豊富であると考えられます ( 4.3年の平均在任期間)。

Vertex Pharmaceuticals マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 15, 2024

Vertex Pharmaceuticals Incorporated Appoints Nancy Thornberry to Its Board of Directors as an Independent Director

Vertex Pharmaceuticals Incorporated Appoints Michel Lagarde to Its Board of Directors

Vertex Pharmaceuticals Incorporated Appoints E. Morrey Atkinson, Ph.D., as Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

Vertex Pharmaceuticals Incorporated Appoints Jonathan Biller as Chief Legal Officer, Effective September 19, 2022

Recent updates

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director

Vertex Pharmaceuticals Incorporated Re-Iterates Earnings Guidance for the Full Year 2024

Vertex Pharmaceuticals Announces European Commission Approval for KALYDECO to Treat Infants with Cystic Fibrosis Ages 1 Month and Older

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Vertex Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 06, 2024

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 15, 2024

Vertex Pharmaceuticals Incorporated Announces New Drug Submission for Exagamglogene Autotemcel (Exa-Cel) Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Positive Results from Pivotal Trials of Vanza Triple Combination Treatment for Cystic Fibrosis

Vertex Pharmaceuticals Incorporated Provides Product Revenue Guidance for the Full Year 2024

Vertex Announces Positive Results from the VX-548 Phase 3 Program for the Treatment of Moderate-To-Severe Acute Pain

Vertex Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 05, 2024

Vertex Pharmaceuticals Incorporated Announces US FDA Approval of CASGEVY™ (Exagamglogene Autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Kingdom of Saudi

Vertex Pharmaceuticals Incorporated Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

Vertex Pharmaceuticals Incorporated Appoints Nancy Thornberry to Its Board of Directors as an Independent Director

Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older

Vertex Pharmaceuticals Incorporated Announces European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5

Vertex Pharmaceuticals Incorporated Announces United Kingdom Medicines and Healthcare Products Regulatory Agency Granted Conditional Marketing Authorization for CASGEVY

Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Market Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With at Least One F508del Mutation

Vertex Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 06, 2023

Vertex Pharmaceuticals Incorporated Appoints Michel Lagarde to Its Board of Directors

Vertex Pharmaceuticals Incorporated Receives Chmp Positive Opinion for Kaftrio® (Ivacaftor/Tezacaftor/Elexacaftor) in Combination with Ivacaftor for Children with Cystic Fibrosis Ages 2 Through 5

Vertex Pharmaceuticals Incorporated Appoints E. Morrey Atkinson, Ph.D., as Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

Vertex Pharmaceuticals Incorporated Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine

Vertex Pharmaceuticals Incorporated Announces European Commission Approval for ORKAMBI® (Lumacaftor/Ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 1 to <2 Years Old

Vertex Pharmaceuticals Incorporated Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions

Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) announces an Equity Buyback for $3,000 million worth of its shares.

Vertex Pharmaceuticals Incorporated to Report Q4, 2022 Results on Feb 07, 2023

Vertex Pharmaceuticals Incorporated Announces to Present New Data on its Portfolio of Cystic Fibrosis Medicines at 2022 North American Cystic Fibrosis Conference

Vertex Pharmaceuticals Incorporated Revises Revenue Guidance for the Fiscal 2022

Vertex Pharmaceuticals Incorporated to Report Q3, 2022 Results on Oct 27, 2022

Vertex Pharmaceuticals Incorporated Advances Program Targeting Alpha-1 Antitrypsin Deficiency

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

Vertex Pharmaceuticals Incorporated Appoints Jonathan Biller as Chief Legal Officer, Effective September 19, 2022

Vertex Pharmaceuticals Incorporated Appoints Jonathan Biller as Chief Legal Officer, Effective September 19, 2022

Vertex Announces U.S. FDA Approval for Orkambi® (Lumacaftor/Ivacaftor) in Children with Cystic Fibrosis Ages 12 to <24 Months

Vertex Pharmaceuticals Incorporated Reports Unaudited Intangible Asset Impairment Charge for the Three Months Ended June 30, 2022

Vertex Advances VX-548 in Acute and Neuropathic Pain

Vertex Pharmaceuticals Incorporated to Report Q2, 2022 Results on Aug 04, 2022

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into a definitive agreement to acquire ViaCyte, Inc. from Sanderling Ventures, RA Capital Management, L.P., The Invus Group, LLC, Asymmetry Ventures LLC and others for approximately $320 million.

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into a definitive agreement to acquire ViaCyte, Inc. from Sanderling Ventures, RA Capital Management, L.P., The Invus Group, LLC, Asymmetry Ventures LLC and others for approximately $320 million.

Vertex Announces FDA Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes

Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference

Vertex Pharmaceuticals Incorporated Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA

Vertex Pharmaceuticals Incorporated to Present New Data on VX-880 Clinical Trial

Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million.

Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million.

Vertex Pharmaceuticals Incorporated Elects Suketu Upadhyay as Independent Director

Vertex Pharmaceuticals Incorporated Reiterates Earning Guidance for 2022

Vertex Pharmaceuticals Incorporated to Report Q1, 2022 Results on May 05, 2022

Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for TRIKAFTA in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 18, 2022

Vertex Pharmaceuticals Incorporated Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain

Vertex Pharmaceuticals Incorporated Announces Reimbursement Agreement in Australia for TRIKAFTA

Vertex Pharmaceuticals Incorporated Provides Full Year 2022 Financial Guidance

Vertex Pharmaceuticals Incorporated announces European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor)

Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis

Vertex Pharmaceuticals Incorporated Announces Its Supplement to a New Drug Submission for PrKALYDECO

Vertex Pharmaceuticals Incorporated Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) announces an Equity Buyback for $1,500 million worth of its shares.

Health Canada Grants Marketing Authorization for Vertex Pharmaceuticals Incorporated TRIKAFTA®

マネジメント基準チェック /24